These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1789811)

  • 21. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors].
    Ogawa H; Kojima S; Sakamoto T
    Nihon Ronen Igakkai Zasshi; 2009 Jan; 46(1):26-8. PubMed ID: 19246828
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins and risk of coronary heart disease.
    Clemenson ND
    JAMA; 2000 Jun; 283(22):2935; author reply 2936. PubMed ID: 10865266
    [No Abstract]   [Full Text] [Related]  

  • 26. Statins and risk of coronary heart disease.
    Ebrahim S; Smith GD
    JAMA; 2000 Jun; 283(22):2935-6. PubMed ID: 10865267
    [No Abstract]   [Full Text] [Related]  

  • 27. Beyond statins: what to expect from add-on lipid regulating therapy?
    Laufs U; Weintraub WS; Packard CJ
    Eur Heart J; 2013 Sep; 34(34):2660-5. PubMed ID: 23832488
    [No Abstract]   [Full Text] [Related]  

  • 28. [Guideline for management of lipid metabolism].
    Ishibashi S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
    [No Abstract]   [Full Text] [Related]  

  • 29. Gauging the impact of statins using number needed to treat.
    Kumana CR; Cheung BM; Lauder IJ
    JAMA; 1999 Nov; 282(20):1899-901. PubMed ID: 10580441
    [No Abstract]   [Full Text] [Related]  

  • 30. How do HMG-CoA reductase inhibitors prevent stroke?
    Bedi A; Flaker GC
    Am J Cardiovasc Drugs; 2002; 2(1):7-14. PubMed ID: 14727994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug therapy for lipid disorders. Selecting appropriate lipid-lowering agents.
    LaRosa JC
    Postgrad Med; 1987 Jul; 82(1):103-11. PubMed ID: 3601832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fighting high cholesterol levels--lipid lowering drugs.
    Fidge NH
    Med J Aust; 1993 Dec 6-20; 159(11-12):815-9. PubMed ID: 8264477
    [No Abstract]   [Full Text] [Related]  

  • 34. [Stroke prevention by statins].
    Sawada N; Itoh H; Nakao K
    Nihon Rinsho; 2002 May; 60(5):993-1001. PubMed ID: 12030004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [HMG-CoA reductase inhibitors (statin)].
    Yamamura T; Ishigami M
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():458-64. PubMed ID: 17824071
    [No Abstract]   [Full Text] [Related]  

  • 36. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents.
    Gordon DJ; Rifkind BM
    Ann Intern Med; 1987 Nov; 107(5):759-61. PubMed ID: 3662286
    [No Abstract]   [Full Text] [Related]  

  • 37. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    Lopez LM
    Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The analysis by Manuel and colleagues creates controversy with headlines, not data.
    Genest J; McPherson R; Frohlich J; Fodor G
    CMAJ; 2005 Apr; 172(8):1033-4; discussion 1037. PubMed ID: 15824410
    [No Abstract]   [Full Text] [Related]  

  • 39. Current perspectives on statins.
    Maron DJ; Fazio S; Linton MF
    Circulation; 2000 Jan; 101(2):207-13. PubMed ID: 10637210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
    Järvisalo MJ; Toikka JO; Vasankari T; Mikkola J; Viikari JS; Hartiala JJ; Raitakari OT
    Atherosclerosis; 1999 Dec; 147(2):237-42. PubMed ID: 10559508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.